HPV Associated Disorder Market Trends, Research Report, Growth, Opportunities, Forecast 2022-2028

The global HPV associated disorder market is anticipated to showcase considerable growth during the forecast period. Human papillomavirus (HPV) is a common sexually transmitted infection. The high incidence and prevalence rate of HPV associated disorder along with the product advancement by the key players operating in the HPV associated disorder market by the key players operating in the market across the globe is making a considerable contribution towards the growth of the HPV associated disorder market across the globe. Anogenital warts, recurrent respiratory papillomatosis, cervical cancer, anogenital and oropharyngeal cancers are among the common HPV associated disorders.

A full report of HPV Associated Disorder Market is available at: https://www.omrglobal.com/industry-reports/hpv-associated-disorder-market

According to the Center for Disease and Control Prevention (CDC), nearly 44,000 HPV-associated cancers occur in the US every year, among them nearly 25,000 among women, and nearly 19,000 among men. The high incidence rate of HPV associated disorder across the globe is creating demand for its treatment thereby making a huge contribution towards the growth of the global HPV associated disorder market.

Johnson & Johnson Services, Inc., Pfizer Inc., Merck & Company, Inc., GlaxoSmithKline Plc., Eli Lily and Company, F. Hoffmann-La Roche Ltd., AstraZeneca plc, Biocon Ltd., Novartis AG, Allergen plc, and so on are among the major players operating in the global HPV associated disorder market. Product launch, partnerships, collaboration, and mergers and acquisition among others are the major growth strategies being adopted by the major market players to stay competitive in the global HPV associated disorder market.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hpv-associated-disorder-market

Recent Developments in the Global HPV associated Disorder Market

• In June 2018, Merck KgaA had announced that the US FDA has accepted its application to expand the application areas of Gardasil 9. As per the approval letter, Gardsil 9 can now be used for the patients whether men or women aged 27-45. The use of Gardsil 9 facilitates the prevention of HPV-associated cancers and other disorders.
• In July 2019, Merck KgaA had announced to increase their supply of HPV drugs for China region as the demand for HPV vaccines have increased significantly.

Global HPV Associated Disorder Market Segmentation

By Indication

• Cervical Intraepithelial Neoplasia (CIN)
• Cervical Cancer
• Anal Intraepithelial Neoplasia (AIN)
• Anal Cancer
• Genital Warts

By Therapy Type

• Prevention
• Therapy

Global HPV Associated Disorder Market - Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Advaxis, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Biocon, Ltd.
• Cytovation AS
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Company, Inc.
• Pfizer, Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.